Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SELENOMETHIONINE SE 75.
MPI DMSA KIDNEY REAGENT vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical